# OnCo record nct04454437 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct04454437/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct04454437", "NCT04454437" ;
  schema:name "Study of Sacituzumab Govitecan in Chinese Patients With Metastatic Triple-negative Breast Cancer Who Received at Least Two Prior Treatments"@en ;
  schema:description "A phase 2 trial of Sacituzumab govitecan in triple-negative breast cancer, run by Gilead Sciences, active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct04454437/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT04454437> ;
  onco:status "active" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "2" ;
  schema:startDate "2020-10-23" ;
  onco:cancers <https://onco.cc/cancers/tnbc/>, <https://onco.cc/cancers/tnbc-metastatic/> ;
  onco:technologies <https://onco.cc/technologies/adc/>, <https://onco.cc/technologies/topoisomerase-inhibitors/> ;
  onco:drugs <https://onco.cc/drugs/sacituzumab-govitecan/> ;
  onco:companies <https://onco.cc/companies/gilead/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-nct04454437-int-j-cancer-2023/> .